# US 2016/0235664 A1 · Hematocrit modulation through needle assisted jet injection of testosterone

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0235664 A1
- Document ID: US20160235664A1
- Status: Published application
- Kind: A1
- Application number: 15/027,387
- Filed: 2014-10-07
- Published: 2016-08-18
- Earliest claimed: 2013-10-07
- Assignees: Antares Pharma, Inc.
- Inventors: Paul K. Wotton; Jonathan Jaffe
- Web page: https://patentgrep.com/patent/US20160235664A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/568: substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61M 5/20: Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically (A61M5/142 takes precedence)
- A61M 5/2033: {Spring-loaded one-shot injectors with or without automatic needle insertion (multishot dosing syringes A61M5/31525, needle insertion only A61M5/3287)}
- A61M 5/30: Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or carpules
- A61P 5/24: of the sex hormones
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted jet injection device.

## Claims

### Claim 1

A method of modulating or controlling the level of hematocrit in the blood of a subject, who is susceptible to a change in his or her hematocrit blood levels in response to a change in testosterone blood levels, comprising administering to the subject, in need of such a treatment, testosterone or a pharmaceutically acceptable ester or salt thereof, such that the maximum concentration of the testosterone or the pharmaceutically acceptable ester or salt thereof in the blood (serum or plasma) of the subject, following administration of a dose of the testosterone or of the pharmaceutically acceptable ester or salt thereof to the subject (“Cmax”), is maintained at a value from about 300 ng/dl to about 1800 ng/dl.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject has an age of about at least 60 years.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject has an age of about at least 65 years.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject has an age of about at least 70 years.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject has an age of about at least 75 years.

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject has an age of from about 60 years to 75 years.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject as an age of from about 60 years to 70 years.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject has an age of bout 75 years.

### Claim 9 (depends on 1)

The method of claim 1, wherein the level of hematocrit produced in the subject is maintained at or below the baseline hematocrit but below or about a level of hemoatocrit defined by the following equation:
Baseline Hematocrit+X*Baseline Hematocrit
wherein X is selected from a value at or about 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, or 0.6.

### Claim 10 (depends on 1)

The method of claim 1, wherein the level of hematocrit produced in the subject following a subcutaneous administration of the dose of the testosterone or the pharmaceutically acceptable ester or salt thereof does not exceed a value selected from 54%, 60%, 65%, and 70%.

### Claim 11 (depends on 1)

The method of claim 1, wherein the level of hematocrit produced in the subject following a subcutaneous administration of the dose of the testosterone or the pharmaceutically acceptable ester or salt thereof does not exceed a value selected from 46%, 50% and 60%.

### Claim 12 (depends on 1)

The method of claim 1, wherein the level of hematocrit produced in the subject following a subcutaneous administration of the dose of the testosterone or the pharmaceutically acceptable ester or salt thereof to the subject is maintained at or about a normal (e.g., baseline) value, but below the level of hematocrit produced in the subject following an intramuscular administration of the same dose of the testosterone or the pharmaceutically acceptable ester or salt thereof.

### Claim 13 (depends on 1)

The method of claim 1, wherein a subcutaneous administration of the dose of the testosterone or the pharmaceutically acceptable ester or salt thereof to the subject produces a level of hematocrit is maintained at or about a normal (e.g., baseline) value, but below a hematocrit level selected from group consisting of 54%, 60%, 65%, and 70%.

### Claim 14 (depends on 1)

The method of claim 1, wherein the subject is a male.

### Claim 15 (depends on 1)

The method of claim 1, wherein the subject is a female.

### Claim 16 (depends on 1)

The method of claim 1, wherein the subject is a newborn.

### Claim 17 (depends on 1)

The method of claim 1, wherein the testosterone or a pharmaceutically acceptable ester or salt thereof is administered to the subject through a subcutaneous injection using a needle-assisted jet injector.
